Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Cosmetic – antiperspirant – dentifrice
Patent
1997-06-23
2000-10-31
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Cosmetic, antiperspirant, dentifrice
4241951, 514847, 514848, 514859, 514881, 514887, A61K 748
Patent
active
061398500
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to compositions and formulations, and methods for using the same, to inhibit skin irritation in animals.
BACKGROUND
Many substances are applied topically to the skin or mucous membranes of humans or animals (hereafter "skin") in order to alter the subject's appearance, to protect the subject from the environment, or to produce a biological change in the skin or other tissue for therapeutic, preventive or cosmetic purposes. These substances may generically be termed "topical products" and include such topically applied substances as cosmetics, over-the-counter and prescription topical drugs, and a variety of other products such as soaps and detergents.
Topical products occur in a variety of forms, including solids, liquids, suspensions, semisolids (such as creams, gels, pastes or "sticks"), powders or finely dispersed liquids such as sprays or mists. Examples of topical products commonly classified as "cosmetics" include skin care products such as creams, lotions, moisturizers and "treatment cosmetics" such as exfoliants and/or skin cell renewal agents; fragrances such as perfumes and colognes, and deodorants; shaving-related products such as creams, "bracers" and aftershaves; depilatories and other hair removal products; skin cleansers, toners and astringents; pre-moistened wipes and washcloths; tanning lotions; bath products such as oils; eye care products such as eye lotions and makeup removers; foot care products such as powders and sprays; skin colorant and make-up products such as foundations, blushes, rouges, eye shadows and liners, lip colors and mascaras; lip balms and sticks; hair care and treatment products such as shampoos, conditioners, colorants, dyes. bleaches, straighteners, and permanent wave products; baby products such as baby lotions, oils, shampoos, powders and wet wipes; feminine hygiene products such as deodorants and douches; skin or facial peels applied by dermatologists or cosmeticians; and others. Examples of topical products commonly classified as "topical drugs" are many and varied, and include over-the-counter and/or prescription products such as antiperspirants, insect repellents, sunscreens and sunburn treatments, anti-acne agents, antibiotics, topical respiratory agents, ocular drugs such as eyedrops and saline solutions, therapeutic retinoids, anti-dandruff agents, external analgesics such as capsaicin products, topical contraceptives, topical drug delivery systems, gastrointestinal agents such as suppositories, enemas and hemorrhoid treatments, reproductive system agents such as vaginal treatments, oral treatments such as lozenges, and many other products with therapeutic or other effects. Other topical products include hand, facial and body soaps and detergents and other forms of skin cleansers, as well as household detergents and many other household products such as solvents, propellants, polishes, lubricants, adhesives, waxes and others which are either applied topically or are topically exposed to the body during normal use.
In a large number of cases, topical products contain chemicals which may produce "irritation," including various inflammation symptoms or signs, when applied to the skin or mucosa ("skin"). The present invention is directed in part to compositions and methods for inhibiting the irritation associated with such topical products.
The occurrence, frequency and nature of topical-product-induced irritation often varies from user to user. The severity of irritation to the susceptible user may range from subclinical to mild to severe. Typical symptoms of "irritation" include itching (pruritus), stinging, burning, tingling, "tightness," erythema (redness) or edema (swelling). The irritation response may be due to the direct effect on the skin of certain topical product chemicals or to a response by the immune system directed toward the chemicals alone or in combination with skin components (e.g. antigens).
The sensation of itch is one of the most common skin problems experienced by humans and animals. Itch can be
REFERENCES:
patent: 3716054 (1973-02-01), Porter et al.
patent: 4105782 (1978-08-01), Yu et al.
patent: 4105783 (1978-08-01), Yu et al.
patent: 4191750 (1980-03-01), Hodosh
patent: 4285973 (1981-08-01), Edwards
patent: 4388301 (1983-06-01), Klein
patent: 4477439 (1984-10-01), D'Alelio
patent: 4943432 (1990-07-01), Biener
patent: 4971800 (1990-11-01), Chess et al.
patent: 5262153 (1993-11-01), Mishima et al.
patent: 5716625 (1998-02-01), Hahn et al.
patent: 5804203 (1998-09-01), Hahn et al.
patent: 5824650 (1998-10-01), De Lacharriere et al.
patent: 5851556 (1998-12-01), Breton et al.
patent: 5866168 (1999-02-01), De Lacharriere et al.
patent: 5972892 (1999-10-01), De Lacharriere et al.
Y. Zyuzyukin et al., "Local Action of Strontium Compounds," Chemical Abstracts 1973:12, pp. 100-101, Abstract No. 80:78918 (1973).
The Merck Index, 11th Ed., 1989, pp. 1394-1395.
Bilotto, Gerardo, et al., "Effects of Ionic and Non-Ionic Solutions on Intradental Nerve Activity in the Cat," Pain, 32: 231-238, 1988.
Celerier, et al., "Modulatory Effects of Selenium and Strontium Salts on Keratinocyte-Derived Inflammatory Cytokines," Arch. Dermatol. Res., vol. 287, pp. 680-682 (1985).
Foreman, J.C. et al., "Movement of Strontium Ions into Mast Cells and its Relationship to the Secretory Response," J. Physiol., 271:233-251, 1977.
Frankenhaeuser, Bernhard, et al., "The Effect of Magnesium and Calcium on the Frog Myelinated Nerve Fibre," J. Physiol., 142: 360-365, 1958.
Gutentag, Herb, "The Effect of Strontium Chloride on Peripheral Nerve in Comparison to the Action of `Stabilizer` and `Labilizer` Compounds," Penn. Dental Journal, 68(2): 37-43, Feb. 1965.
Kato, G., et al., "Anaesthetic Action of Magnesium Ions," Can. Anaes. Soc. J., 15(6): 539-544, Nov. 1968.
Kim, Syngcuk, "Hypersensitive Teeth: Desensitization of Pulpal Sensory Nerves," J. Endodontics, 12(10): 482-485, Oct. 1986.
Markowitz, K., et al., "Decreasing Intradental Nerve Activity in the Cat with Potassium and Divalent Cations," Archs. Oral Biol., 36(1): 1-7, 1991.
Markowitz, K., et al., "The Role of Selected Cations in the Desensitization of Intradental Nerves," Proc. Finn. Dent. Soc., 88 (Suppl I): 39-54, 1992.
Orchardson, R., "Is Calcium More Effective than Strontium as a Desensitizing Agent for Dentine?," in Lesney & Matthew (eds.), Current Topics in Oral Biology, Univ. of Bristol Press (Bristol, 1985), pp. 205-215.
Penny, Deborah, et al., "Fast Desensitization of Tooth Roots by Topically Applied SnF.sub.2 and SrCl.sub.2 in Dogs," Archs. Oral Biol., 21(6): 339-347, 1976.
Shioya, Takao, et al., "Fast and Slow Blockades of the Inward-Rectifier K.sup.+ Channel by External Divalent Cations in Guinea-Pig Cardiac Myocytes," Pflugers Arch., 422: 427-435, 1993.
Sohn et al, "Agonist-Independent, Muscle-Type-Specific Signal Transduction Pathways in Cat Esophageal and Lower Esophageal Sphincter Circular Smooth Muscle," J. Pharmacol. & Exp. Therap., vol. 273, No. 1, pp. 482-491 (1995).
Sohn et al, "Different Receptors Activate a Different Single G-Protein in Esophageal (G.sub.i3) and in LES (G.sub.q) Circular Smooth Muscle," Gastroenterology, vol. 104, abstract p. A585 (Apr. 1993).
Abel, Elizibeth, A., "Phototherapy", Dematologic Clinics, 13(4):841-849, Oct. 1995.
Arky, Ronald, et al. (Eds.), Physicians Desk Reference, 49.sup.th Edition, 1995, p. 929.
Fitzpatrick, Thomas B., et al. (Eds.), Dermatology in General Medicine, (McGraw-Hill, Inc. 1993), 4.sup.th Ed., vol. 1, pp. 501, 508-510, 1393-1396.
Gilman, Alfred Goodman, et al., The Pharmacological Basis of Therapeutics, (McGraw-Hill, Inc.,1993), pp. 769-771, 1291, 1518-1519, 1581,1586.
Gonzalez, Ernesto, "PUVA for Psoriasis," Dermatological Clinics, 13(4): 851-866, Oct. 1995.
Greaves, Malcolm W., et al., "Treatment of Psoriasis," New England J. Med., 332(9):581-588, Mar. 1995.
Griffiths, Tamara W., et al., "Immunopathogenesis and Immunotherapy of Psoriasis," Dermatological Clinics, 13(4): 739-749, Oct. 1995.
Jeffes III, Edward W.B., et al., "Methotrexate and Other Chemotherape
Hahn Gary S.
Thueson David O.
Channavajjala L.
Cosmederm Technologies
Page Thurman K.
LandOfFree
Formulations and methods for reducing skin irritation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations and methods for reducing skin irritation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations and methods for reducing skin irritation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2048067